

Reference number(s)

6476-A

Specialty Guideline Management Anktiva

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Overthe-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Anktiva	nogapendekin alfa inbakicept-pmln

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

Anktiva is indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Bladder Cancer¹

Authorization of 6 months may be granted for treatment of bladder cancer when all of the following criteria are met:

Anktiva SGM 6476-A P2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s) 6476-A

- The member has non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
- The disease is Bacillus Calmette-Guerin (BCG)-unresponsive
- The requested medication will be used in combination with Bacillus Calmette-Guerin (BCG)
- The member will receive maintenance doses at months 4, 7, 10, 13 and 19 after induction therapy.

Continuation of Therapy

Authorization of 12 months [for a total of 24 maintenance doses (37 months of treatment)] may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease recurrence or progression while on the current regimen.

References

1. Anktiva [package insert]. Bothell, WA: AGC Biologics; April 2024.